Understanding the mental health of doctoral researchers: a mixed methods systematic review with meta-analysis and meta-synthesis.

Data from studies with undergraduate and postgraduate taught students suggest that they are at an increased risk of having mental health problems, compared to the general population. By contrast, the literature on doctoral researchers (DRs) is far more disparate and unclear. There is a need to bring together current findings and identify what questions still need to be answered. We conducted a mixed methods systematic review to summarise the research on doctoral researchers' (DRs) mental health. Our search revealed 52 articles that were included in this review. The results of our meta-analysis found that DRs reported significantly higher stress levels compared with population norm data. Using meta-analyses and meta-synthesis techniques, we found the risk factors with the strongest evidence base were isolation and identifying as female. Social support, viewing the PhD as a process, a positive student-supervisor relationship and engaging in self-care were the most well-established protective factors. We have identified a critical need for researchers to better coordinate data collection to aid future reviews and allow for clinically meaningful conclusions to be drawn. PROSPERO registration CRD42018092867

Business and Human Rights: An Oxfam perspective on the UN Guiding Principles

This briefing outlines the responsibility of businesses to respect human rights under the UN Guiding Principles on Business and Human Rights (UNGPs), also known as the Ruggie Framework. It provides an overview of the UNGPs and gives an Oxfam perspective, including case studies, on key issues for businesses

Predictors of Covid-19 anxiety in UK university students

Aim: The current research aimed to evaluate UK student mental health during the first four months of the COVID-19 pandemic. Specifically, we were interested in exploring factors that contribute to students’ anxiety levels about COVID-19. Demographics, mental health symptomatology and wellbeing-related variables were tested as predictors of COVID-19 anxiety. Methods: A cross-sectional online survey was completed by 1,164 UK university students (71.8% females). Measures included self-reported data on stress, social phobia, anxiety, depression, psychotic-like experiences, hopefulness, group membership, social identity, belonging, loneliness, COVID-19 related variables and demographics. The majority of participants were between 18-24 years old (92.2%), White British (57.9%) and in the first or second year of their course study (63.12%). Findings: A series of multiple linear regressions revealed that being female, experiencing more stress and anxiety, and greater worry about COVID-19 and its effects on social relationships were significant in explaining students’ pandemic-related anxiety. Students’ level of pandemic-related anxiety was independent of ethnicity, socioeconomic background and pre-existing mental health problems. Worrying about the future was the most common pandemic-related stressor, but it was not a significant predictor of COVID-19 anxiety. Conclusion: Our findings are in line with previous findings that females and students experiencing more stress have been disproportionately affected by the COVID-19 pandemic. Our findings could inform the delivery of targeted stress-management interventions which might prove beneficial for student wellbeing

Nationwide assessment of the mental health of UK Doctoral Researchers

Doctoral Researchers (DRs) are an important part of the academic community and, after graduating, make substantial social and economic contributions. Despite this importance, DR wellbeing has long been of concern. Recent studies have concluded that DRs may be particularly vulnerable to poor mental health problems, but direct comparisons of the prevalence of mental health problems between them and a control group is lacking. Here, by comparing DRs with educated working controls, we show that DRs report significantly greater anxiety and depression, and that this difference is not explained by a higher rate of pre-existing mental health problems. Moreover, most DRs perceive poor mental health as a ‘normal’ part of the PhD process. Thus, our findings suggest a hazardous impact of PhD study on mental health, with DRs being particularly at risk of developing common mental health problems. This provides an evidence-based mandate for universities and funders to reflect upon practices related to DR training and mental health. Our attention should now be directed towards understanding what factors may explain heightened anxiety and depression among DRs so as to inform preventative measures and interventions

Author Correction: High- or low-dose preoperative ipilimumab plus nivolumab in stage III urothelial cancer: the phase 1B NABUCCO trial (Nature Medicine, (2023), 29, 3, (588-592), 10.1038/s41591-022-02199-y)

Correction to: Nature Medicine. Published online 2 February 2023. In the version of this article initially published, the first name of Antoine G. van der Heijden was misspelled as “Toine” and has now been corrected in the HTML and PDF versions of the article

High- or low-dose preoperative ipilimumab plus nivolumab in stage III urothelial cancer: the phase 1B NABUCCO trial

Cohort 1 of the phase 1B NABUCCO trial showed high pathological complete response (pCR) rates with preoperative ipilimumab plus nivolumab in stage III urothelial cancer (UC). In cohort 2, the aim was dose adjustment to optimize responses. Additionally, we report secondary endpoints, including efficacy and tolerability, in cohort 2 and the association of presurgical absence of circulating tumor DNA (ctDNA) in urine and plasma with clinical outcome in both cohorts. Thirty patients received two cycles of either ipilimumab 3 mg kg−1 plus nivolumab 1 mg kg−1 (cohort 2A) or ipilimumab 1 mg kg−1 plus nivolumab 3 mg kg−1 (cohort 2B), both followed by nivolumab 3 mg kg−1. We observed a pCR in six (43%) patients in cohort 2A and a pCR in one (7%) patient in cohort 2B. Absence of urinary ctDNA correlated with pCR in the bladder (ypT0Nx) but not with progression-free survival (PFS). Absence of plasma ctDNA correlated with pCR (odds ratio: 45.0; 95% confidence interval (CI): 4.9–416.5) and PFS (hazard ratio: 10.4; 95% CI: 2.9–37.5). Our data suggest that high-dose ipilimumab plus nivolumab is required in stage III UC and that absence of ctDNA in plasma can predict PFS. ClinicalTrials.gov registration: NCT03387761

Abstracts From The 3Rd International Severe Asthma Forum (Isaf)

PubMe